Main Article Content
The purpose of our study was to evaluate the efficacy and tolerability of nasal spray Laferobionum® (100,000 IU/ml)
in children with acute respiratory viral infections. Materials and methods. The study included 84 children aged 12 to 18 years. Children of the main group (42 persons) received Laferobionum® spray in addition to the standard treatment for acute respiratory viral infections. The drug was administered to children of 12–14 years for 2 spray doses in each nasal passage 4–5 times a day at regular intervals (with the exception of sleep time), children aged 14–18 years received 3 spray-doses per each nasal passage 5–6 times a day at regular intervals (excluding sleep time). The course of treatment for all subjects was 5 days. Children of the control group received standard treatment for acute respiratory viral infections without Laferobionum®. Objective research included: auscultation of the heart and lungs, examination of the skin and mucous membranes, measurement of heart rate, blood pressure and body temperature. All patients underwent a general blood test, a general urinalysis, identification of the pathogen using the method of direct immunofluorescence (in smears taken from the nasal passages) in the laboratory “Medical Diagnostic Center of Dnipropetrovsk Medical Academy”. Results. In the non-epidemic period, the respiratory syncytial virus and adenoviruses were the leading viral pathogens of acute respiratory viral infections. The main clinical manifestations of acute respiratory viral infection in the observed patients were signs of general inflammatory and catarrhal syndromes. All patients had not severe course of the disease. The data of the physical examination performed before the beginning of treatment indicated the absence of clinically significant deviations from the cardiovascular system in the children of the main and control groups. Arterial blood pressure and heart rate in the subjects of both groups were within the age limit and corresponded to the temperature response. Analyzing the dynamics of clinical symptoms of acute respiratory viral infection in both groups, it should be noted that there was a persistent tendency to lower body temperature in patients, both in the main and control groups. However, in the group of patients receiving Laferobionum®, the decrease in the temperature curve occurred faster, its normalization was noted already on the 4th day of therapy in 100 % of patients, whereas in the control group on the 4th day of the disease the body temperature remained subfebrile in 12 (28.6 %), on the 5th day — in 2 (4.8 %) children. Complete blood count in children of the main and control groups at the beginning of the disease showed leukopenia of varying severity, relative lymphocytosis, and accelerated erythrocyte sedimentation rate (ESR). On the 5th day of therapy in patients of the main group, the number of leukocytes was normalized, the relative lymphocytosis persisted against the background of a decrease in ESR. While in the control group, the number of leukocytes in peripheral blood remained lower with an elevated level of ESR. During the whole period of observation, the presence and nature of possible complications of acute respiratory viral infection was assessed. The total duration of the observation period was 14 days. During the observation period, no complications were detected in any of the patients in the main or control groups. During the time of the clinical trial, no adverse reactions were recorded that could be associated with the administration of Laferobionum®. There were no cases of exacerbation of existing chronic diseases in the children of the main group, while 1 (2.4 %) person from the control group had exacerbation of chronic tonsillitis. Evaluation of the effectiveness of therapy with the drug was carried out on the 5th day of treatment. Since one of the effectiveness criteria was the absence of clinical signs of the disease at the end of therapy, we calculated the proportion of patients in groups, who didn’t have clinical signs of acute respiratory viral infection (more than 1 point) after 5 days of treatment. The effectiveness of therapy with Laferobionum® was 100 %. The effectiveness of treatment with Laferobionum® depended to some extent on the etiology of the disease: in acute respiratory viral infections caused by the respiratory syncytial virus, there was less significant effect of interferon therapy on the course of the disease than in acute respiratory infections caused by influenza and parainfluenza viruses. Given the absence of subjective complaints from the examinees and negative changes in an objective and laboratory examination, tolerability of treatment in all patients receiving Laferobionum® was regarded as “good”. Conclusions. Interferon therapy, in particular the use of recombinant α-2b interferons (Laferobionum®), is one of the most important components of the treatment for acute respiratory viral diseases in children. The use of interferon for intranasal administration, which contributes to the sanogenesis of acute respiratory infections, will accelerate the process of recovery, prevent the development of bacterial complications.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our edition uses the copyright terms of Creative Commons for open access journals.
Authors, who are published in this journal, agree with the following terms:
- The authors retain rights for authorship of their article and grant to the edition the right of first publication of the article on a Creative Commons Attribution 4.0 International License, which allows others to freely distribute the published article, with the obligatory reference to the authors of original works and original publication in this journal.
- Directing the article for the publication to the editorial board (publisher), the author agrees with transmitting of rights for the protection and using the article, including parts of the article, which are protected by the copyrights, such as the author’s photo, pictures, charts, tables, etc., including the reproduction in the media and the Internet; for distributing; for the translation of the manuscript in all languages; for export and import of the publications copies of the writers’ article to spread, bringing to the general information.
- The rights mentioned above authors transfer to the edition (publisher) for the unlimited period of validity and on the territory of all countries of the world.
- The authors guarantee that they have exclusive rights for using of the article, which they have sent to the edition (publisher). The edition (the publisher) is not responsible for the violation of given guarantees by the authors to the third parties.
- The authors have the right to conclude separate supplement agreements that relate to non-exclusive distribution of their article in the form in which it had been published in the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.
- The policy of the journal permits and encourages the publication of the article in the Internet (in institutional repository or on a personal website) by the authors, because it contributes to productive scientific discussion and a positive effect on efficiency and dynamics of the citation of the article.
- The rights to the article are deemed transferred by the authors to the edition (the publisher) since the moment of the publication of the article in the printed or electronic version of journal.
Abaturov AE, Volosovets AP, Yulish EI. Indukcija molekuljarnyh mehanizmov nespecificheskoj zashhity respiratornogo trakta [Induction of molecular mechanisms of non-specific protection of respiratory tract]. Kyiv: Privatna drukarnja FO-II Storozhuk OV; 2012. 240 p. (In Russian).
Beketova GV. Interferons in treatment of acute respiratory infections in children. Lіki Ukrainy. 2011;3:106-9. (In Russian).
Besh LV. Evaluating the efficacy of interferon preparations in the treatment of acute respiratory viral infections in sickly children. Zdorov'ye Rebenka. 2015:2(61):32-6. (In Ukrainian). doi: 10.22141/2224-05188.8.131.525.75045.
Zaplatnikov AL, Korovina NA, Girina AA, Suzdalenko AV, Lepiseva IV. Modern capabilities of immonoprophylaxis of acute respiratory infections in frequently ailing children. Pediatricheskaja farmakologija. 2008;1:21-6. (In Russian).
Zakharova IN, Cheburkin AV, Malinovskaya VV, et al. Value of interferon system for immune response formation in children with acute respiratory viral infections. Voprosy prakticheskoj pediatrii. 2009;4(6):38-45. (In Russian).
Kuznetsov SV, Kopeichenko TS. Interferon therapy of acute respiratory viral infections in children. Aktual'naya Infektologiya. 2016;1(10):48-50. (In Ukrainian). doi: 10.22141/2312-413x.1.10.2016.74543.
Lobodanov SA, Faizuloev EB, Nikonova AA, et al. Etiology of ARVI: new aspects. Sanitarnyj vrach. 2011;10:049-52. (In Russian).
Niankovskyi SL, Niankovska OS, Yatsula MS. Clinical features of using interferons in the treatment of acute respiratory viral infections in children. Zdorov'ye Rebenka. 2015;5(64):7-12. (In Ukrainian). doi: 10.22141/2224-05184.108.40.2065.74904.
Tiutiunnikov SV, Antonov YuA, Kuziakin GV, Nalimova IS. Effect of topic recombinant interferon alpha-2b on cytokine concentration in saliva of the patients with influenza A/H1N1. Vestnik sovremennoj klinicheskoj mediciny. 2014;7(Suppl 1):106-12. (In Russian). doi: 10.20969/VSKM.2014.7(suppl.1).1-166.
Channappanavar R, Fehr AR, Vijay R, et al. Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected Mice. Cell Host Microbe. 2016 Feb 10;19(2):181-93. doi: 10.1016/j.chom.2016.01.007.
Davidson S. McCabe TM, Crotta S, et al. IFNλ is a potent anti-influenza therapeutic without the inflammatory side effects of IFNα treatment. EMBO Mol Med. 2016 Sep 1;8(9):1099-112. doi: 10.15252/emmm.201606413.
Gao L, Yu S, Chen Q, et al. A randomized controlled trial of low-dose recombinant human interferons alpha-2b nasal spray to prevent acute viral respiratory infections in military recruits. Vaccine. 2010 Jun 17;28(28):4445-51. doi: 10.1016/j.vaccine.2010.03.062.
Goritzka M, Durant LR, Pereira C, et al. Alpha/beta interferon receptor signaling amplifies early proinflammatory cytokine production in the lung during respiratory syncytial virus infection. J Virol. 2014 Jun;88(11):6128-36. doi: 10.1128/JVI.00333-14.
Nogales A, Martinez-Sobrido L, Topham DJ, et al. NS1 Protein Amino Acid Changes D189N and V194I Affect Interferon Responses, Thermosensitivity, and Virulence of Circulating H3N2 Human Influenza A Viruses. J Virol. 2017 Feb 14;91(5). pii: e01930-16. doi: 10.1128/JVI.01930-16.
Seo SU, Kwon HJ, Ko HJ, et al. Type I interferon signaling regulates Ly6C(hi) monocytes and neutrophils during acute viral pneumonia in mice. PLoS Pathog. 2011 Feb;7(2):e1001304. doi: 10.1371/journal.ppat.1001304.